McMenamin Joseph P
McGuireWoods LLP, Richmond, VA, USA.
Food Drug Law J. 2009;64(1):69-100.
This article considers whether in the wake of an influenza pandemic companies may be exposed to claims of legal liability for failing to provide employees with access to antiviral medications, as the Department of Health and Human Services (HHS) now encourages businesses to do. It begins by describing influenza and influenza pandemics. It then discusses the benefits and limitations of antiviral therapies and the recent creation of antiviral option programs. It concludes by considering whether claims may be brought on the theory that corporate leadership is under a duty to prepare for a pandemic by considering whether to provide access to antiviral protection for employees.
本文探讨了在流感大流行之后,公司是否可能因未按照美国卫生与公众服务部(HHS)目前鼓励企业的做法,为员工提供抗病毒药物而面临法律责任索赔。文章首先描述了流感和流感大流行,接着讨论了抗病毒疗法的益处和局限性以及近期设立的抗病毒选择计划。最后,文章通过考量企业领导层是否有责任通过考虑是否为员工提供抗病毒防护来为大流行做准备这一理论,探讨了是否可能引发索赔。